Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors

Overview

Journal J Nucl Med

Specialty Nuclear Medicine

Date 2017 Oct 14

PMID 29025982

Citations 97

Authors

Thomas A Hope

Emily K Bergsland

Murat Fani Bozkurt

Michael Graham

Anthony P Heaney

Ken Herrmann

James R Howe

Matthew H Kulke

Pamela L Kunz

Josh Mailman

Lawrence May

David C Metz

Corina Millo

Sue ODorisio

Diane L Reidy-Lagunes

Michael C Soulen

Jonathan R Strosberg

Affiliations

Soon will be listed here.

Citing Articles

Ga-DOTATATE PET/CT in the Initial Staging of Well-Differentiated Gastroenteropancreatic and Non-Gastroenteropancreatic Neuroendocrine Tumors: Results of a Prospective Registry.

Metser U, Kulanthaivelu R, Duder J, Hinzpeter R, Singh S, Wong R Cancers (Basel). 2025; 17(3).

PMID: 39941805 PMC: 11815848. DOI: 10.3390/cancers17030434.

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer.

Zhu Z, Xuan W, Wang C, Li C Front Oncol. 2024; 14:1481777.

PMID: 39655078 PMC: 11625809. DOI: 10.3389/fonc.2024.1481777.

Liver transplantation for gastroenteropancreatic neuroendocrine liver metastasis: optimal patient selection and perioperative management in the era of multimodal treatments.

Kasai Y, Ito T, Masui T, Nagai K, Anazawa T, Uchida Y J Gastroenterol. 2024; 60(1):1-9.

PMID: 39547997 PMC: 11717855. DOI: 10.1007/s00535-024-02166-z.

The University of Iowa Neuroendocrine Tumor Clinic.

Howe J, Menda Y, Chandrasekharan C, Bellizzi A, Quelle D, ODorisio M Endocr Pract. 2024; 31(1):4-18.

PMID: 39349242 PMC: 11700786. DOI: 10.1016/j.eprac.2024.09.018.

Theranostics with somatostatin receptor antagonists in SCLC: Correlation of Ga-SSO120 PET with immunohistochemistry and survival.

Mavroeidi I, Romanowicz A, Haake T, Wienker J, Metzenmacher M, Darwiche K Theranostics. 2024; 14(14):5400-5412.

PMID: 39310095 PMC: 11413793. DOI: 10.7150/thno.98819.

References

Sadowski S, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P . Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol. 2015; 34(6):588-96. PMC: 4872030. DOI: 10.1200/JCO.2015.64.0987. View

Lamberts S, Bakker W, Reubi J, Krenning E . Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med. 1990; 323(18):1246-9. DOI: 10.1056/NEJM199011013231805. View

Hofman M, Hicks R . Changing paradigms with molecular imaging of neuroendocrine tumors. Discov Med. 2012; 14(74):71-81. View

Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J . QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529-36. DOI: 10.7326/0003-4819-155-8-201110180-00009. View

Tang L, Untch B, Reidy D, OReilly E, Dhall D, Jih L . Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. Clin Cancer Res. 2015; 22(4):1011-7. PMC: 4988130. DOI: 10.1158/1078-0432.CCR-15-0548. View

Badiee S, Franc B, Webb E, Chu B, Hawkins R, Coakley F . Role of IV iodinated contrast material in 18F-FDG PET/CT of liver metastases. AJR Am J Roentgenol. 2008; 191(5):1436-9. DOI: 10.2214/AJR.07.3750. View

Poeppel T, Binse I, Petersenn S, Lahner H, Schott M, Antoch G . 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011; 52(12):1864-70. DOI: 10.2967/jnumed.111.091165. View

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B . Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017; 376(2):125-135. PMC: 5895095. DOI: 10.1056/NEJMoa1607427. View

Raj N, Valentino E, Capanu M, Tang L, Basturk O, Untch B . Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated. Pancreas. 2016; 46(3):296-301. PMC: 5488281. DOI: 10.1097/MPA.0000000000000735. View

10.

Bettmann M . The ACR Appropriateness Criteria: view from the committee chair. J Am Coll Radiol. 2007; 3(7):510-2. DOI: 10.1016/j.jacr.2006.03.024. View

11.

Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G . Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med. 2009; 50(8):1214-21. DOI: 10.2967/jnumed.108.060236. View

12.

Deppen S, Blume J, Bobbey A, Shah C, Graham M, Lee P . 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. J Nucl Med. 2016; 57(6):872-8. PMC: 5362941. DOI: 10.2967/jnumed.115.165803. View

13.

Schreiter N, Maurer M, Pape U, Hamm B, Brenner W, Froeling V . Detection of neuroendocrine tumours in the small intestines using contrast-enhanced multiphase Ga-68 DOTATOC PET/CT: the potential role of arterial hyperperfusion. Radiol Oncol. 2014; 48(2):120-6. PMC: 4078030. DOI: 10.2478/raon-2014-0012. View

14.

Klimstra D, Modlin I, Coppola D, Lloyd R, Suster S . The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010; 39(6):707-12. DOI: 10.1097/MPA.0b013e3181ec124e. View

15.

Walker R, Smith G, Liu E, Moore B, Clanton J, Stabin M . Measured human dosimetry of 68Ga-DOTATATE. J Nucl Med. 2013; 54(6):855-60. PMC: 4472480. DOI: 10.2967/jnumed.112.114165. View

16.

Glazer E, Tseng J, Al-Refaie W, Solorzano C, Liu P, Willborn K . Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford). 2010; 12(6):427-33. PMC: 3028584. DOI: 10.1111/j.1477-2574.2010.00198.x. View

17.

Yao J, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E . Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2015; 387(10022):968-977. PMC: 6063317. DOI: 10.1016/S0140-6736(15)00817-X. View

18.

Krenning E, Valkema R, Kooij P, Breeman W, Bakker W, deHerder W . Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide. Ital J Gastroenterol Hepatol. 1999; 31 Suppl 2:S219-23. View

19.

Raymond E, Dahan L, Raoul J, Bang Y, Borbath I, Lombard-Bohas C . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):501-13. DOI: 10.1056/NEJMoa1003825. View

20.

Brix G, Lechel U, Glatting G, Ziegler S, Munzing W, Muller S . Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med. 2005; 46(4):608-13. View